Nutex Health (NUTX) EBITDA (2010 - 2026)

Nutex Health has disclosed EBITDA across 17 years of filings, most recently posting $81.3 million for Q1 2026.

• EBITDA for Q1 2026 came in at $81.3 million, up 0.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $276.2 million (up 31.64% YoY), and the FY2025 annual result was $275.6 million, up 110.89% from the prior year.
• EBITDA came in at $81.3 million for Q1 2026 at Nutex Health, up from $30.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $130.4 million in Q3 2025 to a low of -$428.7 million in Q3 2022.
• The 5-year median for EBITDA is $5.3 million (2024), against an average of $2.9 million.
• Across the five-year window, EBITDA tumbled 675.7% in 2022 and soared 5462.83% in 2025, its largest moves.
• Nutex Health's EBITDA stood at -$5.8 million in 2022, then sank by 352.42% to -$26.1 million in 2023, then jumped by 536.83% to $114.2 million in 2024, then plunged by 72.93% to $30.9 million in 2025, then soared by 162.84% to $81.3 million in 2026.
• The last three EBITDA figures came in at $81.3 million (Q1 2026), $30.9 million (Q4 2025), and $130.4 million (Q3 2025), per Business Quant data.